Every 8-K that Abpro Holdings, Inc (ABP) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow ABP and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ABP filings page.
Abpro Holdings, Inc. received notice from the Nasdaq Listing and Hearing Review Council that it reaffirmed a prior decision to delist the company’s securities from Nasdaq. The Council cited Abpro’s failure to meet the minimum equity standard under Nasdaq Listing Rule 5550(b)(1) by the February 16, 2026 deadline set in a November 10, 2025 panel decision.
Abpro expects Nasdaq to file a Form 25 to delist and deregister its securities under Section 12(b) of the Exchange Act. The company expects its common stock and public warrants to continue quotation on the OTC Pink Market under the symbols “ABP” and “ABPWW,” but warns holders about potentially limited information availability, reduced transparency and liquidity, and greater trading volatility.
Abpro Holdings, Inc. reported that Nasdaq’s Hearings Panel has decided to delist its common stock and public warrants because the company did not meet the minimum equity requirement under Nasdaq Listing Rule 5550(b)(1) by February 16, 2026. Trading on Nasdaq is scheduled to be suspended at the open on February 23, 2026.
The company has 15 days from February 18, 2026 to request a review by the Nasdaq Listing and Hearing Review Council and expects to appeal. If no appeal is pursued or successful, Nasdaq is expected to file a Form 25 to delist and deregister the securities under Section 12(b).
After Nasdaq trading is suspended, Abpro expects its common stock and public warrants to be eligible for quotation on the OTC Pink Market under the symbols “ABP” and “ABPWW.” The company warns investors that OTC Pink trading may involve reduced information, lower liquidity, and greater price volatility, and it cannot assure that any broker-dealer will make a market in its securities.
Abpro Holdings, Inc. reported that Nasdaq has notified the company it is no longer in compliance with several board and committee independence listing rules following the recent resignations of two independent directors, creating additional bases for potential delisting from The Nasdaq Capital Market.
Nasdaq cited noncompliance with rules requiring a majority-independent board, a three-member independent audit committee, and a two-member independent compensation committee. Abpro must present its views to a Nasdaq Hearings Panel by February 12, 2026, and has a cure period for the compensation committee extending to certain future shareholder meeting dates.
On February 9, 2026, Abpro appointed M. Fatih Karatas and Mary Gunn as Class II directors and to the audit, compensation, and nominating and corporate governance committees, aiming to address the independence and composition deficiencies. The company notes there is no immediate impact on the listing of its common stock or warrants, but there is no assurance it will regain full compliance or that the Panel will grant continued listing.
Abpro Holdings, Inc. reported that two members of its Board of Directors, Anthony D. Eisenberg and Sooyoung Lee, have resigned from the board and all related committees. Both resignations were effective in late January 2026 and were explicitly stated as not arising from any disagreement with the company, its board, or its management on operations, policies, or practices.
Following these departures, the Board has begun a process to identify and appoint new qualified independent directors to fill the vacancies and to meet applicable Nasdaq Stock Market requirements within the time periods allowed by the Nasdaq Listing Rules.
Abpro Holdings, Inc. entered into an unsecured $147,000 loan agreement with its Chief Executive Officer and Chairman, Miles J.W. Suk, to pay the premium for its directors’ and officers’ liability insurance. The CEO will pay the insurer or broker directly, and the funds may be used only for that insurance cost.
The loan runs for nine months and can be repaid early without penalty. No interest is charged for the first three months after funding; after that, the outstanding principal bears interest at a variable rate equal to three-month Term SOFR plus 2.0% per year, with interest due at maturity or earlier repayment. The loan is unsecured and not guaranteed by any third party.
On January 16, 2026, director Ian McDonald resigned from Abpro’s board and all board committees, with the company stating his resignation was not due to any disagreement over operations, policies, or practices. The board appointed Dr. Byung-Hak Yoon as a Class I director to fill the vacancy, with a term ending at the 2028 annual meeting, and named him to the Audit, Compensation, and Nominating and Corporate Governance Committees. Dr. Yoon, age 51, brings extensive leadership experience in biotechnology and medical companies and will receive the company’s standard compensation for independent directors.
Abpro Holdings, Inc. reported that the U.S. Food and Drug Administration has cleared the Investigational New Drug (IND) application for ABP-102 / CT-P72, its lead multispecific antibody oncology program. The therapy is being co-developed with Celltrion, Inc., and this clearance allows clinical studies of the candidate to begin under the IND. The update was shared via a press release furnished under a Regulation FD disclosure.
Abpro Holdings, Inc. disclosed that it has submitted an investigational new drug (IND) application to the U.S. Food and Drug Administration to initiate a phase 1 clinical trial of its T cell engager candidate ABP-102/CT-P72 for HER2-positive cancers. This marks a step toward first-in-human testing of the therapy, subject to regulatory review.
The update comes via a current report that references a company press release containing further details and includes the release as an exhibit. The company notes that this information is being furnished rather than filed under securities laws, which limits how it is incorporated into other regulatory documents.
Abpro Holdings (ABP) filed an 8-K/A amending Item 7.01 to replace the press release furnished as Exhibit 99.1 dated November 4, 2025. The company states no other changes were made to the original report.
The information under Item 7.01 and Exhibit 99.1 is furnished, not deemed filed for purposes of Section 18 of the Exchange Act, and is not incorporated by reference unless expressly stated.
Abpro Holdings (ABP) reported that it and Celltrion will present new preclinical data for CT-P72/ABP-102, a tetravalent bispecific antibody targeting HER2 and CD3, at the Society for Immunotherapy of Cancer (SITC) 2025 Annual Meeting. The meeting runs November 6–10, 2025 at the Gaylord National Resort and Convention Center in National Harbor, Maryland.
The disclosure was furnished under Item 7.01 (Regulation FD), and a related press release was provided as Exhibit 99.1. This update focuses on scientific progress and does not include financial results or transaction details.
Abpro Holdings, Inc. announced a one-for-thirty reverse stock split that became effective at 5:01 p.m. on October 31, 2025. The company’s common stock will begin trading on a split-adjusted basis on the Nasdaq Global Market on November 3, 2025.
The disclosure was made under Regulation FD via an 8-K, with a press release furnished as Exhibit 99.1.
Abpro Holdings (ABP) announced a one-for-thirty reverse stock split of its common stock, effective at 5:01 p.m. on October 31, 2025. Every 30 shares will be combined into one share, with no change to par value. No fractional shares will be issued; holdings will be rounded up to the next whole share.
Following the split, common shares outstanding will be proportionally reduced from 81,150,000 to approximately 2,705,000. Outstanding stock options and warrants, and their exercise prices, will be adjusted to reflect the new ratio. The company’s transfer agent, Continental Stock Transfer & Trust Company, will handle recordholder communications, while broker-held positions will adjust automatically.
The common stock will begin trading on a split-adjusted basis on November 3, 2025, under the ticker ABP. The new CUSIP for the common stock will be 000847202.
Abpro Holdings (ABP) reported a Nasdaq compliance update. On October 14, 2025, the company received notice that it had not regained compliance with two Nasdaq Global Market standards: the Market Value of Publicly Held Shares requirement of $15,000,000 and the Market Value of Listed Securities requirement of $50,000,000, following a 180-day cure period that ended October 7, 2025.
A hearing before an independent Nasdaq Hearings Panel is scheduled for October 30, 2025, where Abpro plans to present its approach to address the Minimum Bid Price Requirement, MVPHS, and MVLS. Delisting action is stayed pending the Panel’s decision, so ABP common stock and warrants remain listed for now. The company cautioned there is no assurance the Panel will grant continued listing or that compliance can be demonstrated within any extension.
Abpro Holdings reported results of its 2025 annual meeting of stockholders. A 1-for-30 reverse stock split was approved. Ian McDonald was elected as a Class I director until the 2028 annual meeting, and Wolf & Company, P.C. was ratified as independent auditor for the fiscal year ending December 31, 2025.
Voting details: Ian McDonald received 30,544,989 votes for, with 8,122,953 withheld and 10,863,999 broker non-votes. Auditor ratification received 48,873,247 votes for, 380,320 against, and 278,374 abstentions. The reverse stock split at a ratio of 1-for-30 was approved with 26,657,935 votes for.
On the record date, there were 80,166,667 shares outstanding. A quorum was established with 49,531,941 votes represented, approximately 61.8% of eligible votes.
Abpro Holdings, Inc. reports that it has failed to regain compliance with Nasdaq’s minimum bid price requirement of $1.00 per share by the September 29, 2025 deadline. On September 30, 2025, Nasdaq notified the company that its common stock is subject to delisting.
Unless Abpro appeals by October 7, 2025, its common stock would be scheduled for delisting at the opening of business on October 9, 2025. The company plans to request a hearing before a Nasdaq appeal panel, which will temporarily keep its securities trading while the panel reviews its plans to regain compliance.
Abpro cautions that there is no assurance the panel will grant continued listing or that it will meet all Nasdaq requirements within any extension period that might be provided.
Abpro Holdings, Inc. disclosed that its Chief Medical Officer, Dr. Robert J. Markelewicz, Jr., M.D., M.M.Sc., has been furloughed and will be leaving the company. Effective September 30, 2025, the company placed him on furlough through November 30, 2025, during which he will not perform any duties or responsibilities associated with his role. The filing states that his employment will be terminated effective November 30, 2025, signaling a planned transition away from this key executive position.